MX2009009779A - Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr. - Google Patents
Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr.Info
- Publication number
- MX2009009779A MX2009009779A MX2009009779A MX2009009779A MX2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A
- Authority
- MX
- Mexico
- Prior art keywords
- ras
- mutations
- methods
- raf
- present application
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title abstract 5
- 101710113436 GTPase KRas Proteins 0.000 title abstract 4
- 238000009175 antibody therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 3
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a mutaciones de K-ras, a polinucleótidos que codifican polipéptidos de K-ras mutantes, y a métodos para identificar mutaciones de K-ras. La presente invención también se refiere a mutaciones de B-raf, a polinucleótidos que codifican polipéptidos de B-raf mutantes, a vectores que contienen esos polinucleótidos, y a métodos para identificar mutaciones de B-raf. La presente solicitud también se refiere a métodos para diagnosticar cáncer; y métodos y kits para pronosticar la utilidad de los agentes de unión específica anti-EGFr en el tratamiento de tumores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90697607P | 2007-03-13 | 2007-03-13 | |
| PCT/US2008/003327 WO2008112274A2 (en) | 2007-03-13 | 2008-03-11 | K-ras and b-raf mutations and anti-egfr antibody therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009779A true MX2009009779A (es) | 2009-09-23 |
Family
ID=39666021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009779A MX2009009779A (es) | 2007-03-13 | 2008-03-11 | Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20090075267A1 (es) |
| EP (2) | EP2412828B1 (es) |
| JP (3) | JP2010521154A (es) |
| AR (1) | AR065686A1 (es) |
| AU (1) | AU2008226808B2 (es) |
| CA (1) | CA2680330A1 (es) |
| CL (1) | CL2008000716A1 (es) |
| CY (1) | CY1114159T1 (es) |
| DK (1) | DK2412828T3 (es) |
| ES (1) | ES2426814T3 (es) |
| HR (1) | HRP20130764T1 (es) |
| MX (1) | MX2009009779A (es) |
| PE (1) | PE20090690A1 (es) |
| PL (1) | PL2412828T3 (es) |
| PT (1) | PT2412828E (es) |
| RS (1) | RS52932B (es) |
| SI (1) | SI2412828T1 (es) |
| TW (1) | TW200904828A (es) |
| WO (1) | WO2008112274A2 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2370054T3 (es) * | 2005-08-24 | 2011-12-12 | Bristol-Myers Squibb Company | Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico. |
| ITBO20050646A1 (it) | 2005-10-26 | 2007-04-27 | Silicon Biosystem S R L | Metodo ed apparato per la caratterizzazione ed il conteggio di particelle |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| US12366585B2 (en) | 2006-05-18 | 2025-07-22 | Caris Mpi, Inc. | Molecular profiling of tumors |
| AU2007253740A1 (en) | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| PE20081880A1 (es) * | 2007-03-13 | 2008-12-31 | Amgen Inc | Mutaciones de k-ras y terapia con anticuerpos anti-egfr |
| AR065686A1 (es) * | 2007-03-13 | 2009-06-24 | Amgen Inc | Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr |
| ITTO20070771A1 (it) | 2007-10-29 | 2009-04-30 | Silicon Biosystems Spa | Metodo e apparato per la identificazione e manipolazione di particelle |
| US8583380B2 (en) | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
| US10895575B2 (en) | 2008-11-04 | 2021-01-19 | Menarini Silicon Biosystems S.P.A. | Method for identification, selection and analysis of tumour cells |
| GB2463401B (en) | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
| DK3301446T3 (da) * | 2009-02-11 | 2020-06-29 | Caris Mpi Inc | Molekylær tumorprofilering |
| CN101487051B (zh) * | 2009-02-24 | 2011-07-20 | 广州益善生物技术有限公司 | Braf基因突变的检测探针、液相芯片及其检测方法 |
| US9192943B2 (en) | 2009-03-17 | 2015-11-24 | Silicon Biosystems S.P.A. | Microfluidic device for isolation of cells |
| RU2553379C2 (ru) * | 2009-08-24 | 2015-06-10 | Дженентек, Инк. | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
| EP2475390A4 (en) * | 2009-09-09 | 2014-01-01 | Quintiles Transnat Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS |
| CN102115782B (zh) * | 2009-12-30 | 2014-06-18 | 北京雅康博生物科技有限公司 | 用于定量检测K-ras突变的试剂盒 |
| KR20130056855A (ko) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
| EP2542893A2 (en) * | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| WO2011130265A2 (en) * | 2010-04-12 | 2011-10-20 | Response Genetics, Inc. | Kras primers and probes |
| WO2011158061A1 (en) | 2010-06-15 | 2011-12-22 | Alberto Bardelli | Mlk4 gene, a new diagnostic and prognostic marker in cancers |
| RU2565550C2 (ru) | 2010-09-24 | 2015-10-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров |
| WO2012049279A1 (en) | 2010-10-14 | 2012-04-19 | Universitaet Des Saarlandes | MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs |
| WO2012138997A1 (en) | 2011-04-07 | 2012-10-11 | Amgen Inc. | Novel egfr binding proteins |
| ITTO20110990A1 (it) | 2011-10-28 | 2013-04-29 | Silicon Biosystems Spa | Metodo ed apparato per l'analisi ottica di particelle a basse temperature |
| US9023640B2 (en) * | 2011-12-13 | 2015-05-05 | Fundamental Solutions Corporation | Device for rapid detection of infectious agents |
| KR20150038068A (ko) | 2012-08-17 | 2015-04-08 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| CA2886397A1 (en) * | 2012-09-26 | 2014-04-03 | Insight Genetics, Inc. | Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers |
| CN105074009B (zh) * | 2013-03-19 | 2017-09-26 | 凸版印刷株式会社 | Egfr抑制剂的敏感性的预测方法 |
| CN104762371B (zh) | 2014-01-07 | 2021-03-09 | 三星电子株式会社 | 用于预测或监控c-Met抑制剂效力的生物标志物 |
| ES2844229T3 (es) | 2014-05-13 | 2021-07-21 | Univ Texas | Mutaciones génicas y alteraciones en el número de copias de EGFR, KRAS y MET |
| KR20160037666A (ko) | 2014-09-29 | 2016-04-06 | 삼성전자주식회사 | KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측 |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| JP7665280B2 (ja) | 2015-12-22 | 2025-04-21 | アクセス・バスキュラー・インコーポレイテッド | 高強度生体材 |
| US11577008B2 (en) | 2017-06-21 | 2023-02-14 | Access Vascular, Inc. | High strength porous materials incorporating water soluble polymers |
| CN107918013A (zh) * | 2017-09-25 | 2018-04-17 | 浙江天科高新技术发展有限公司 | 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒 |
| CN108085390A (zh) * | 2017-12-29 | 2018-05-29 | 上海桐树生物科技有限公司 | 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用 |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| JP2022514368A (ja) | 2018-12-19 | 2022-02-10 | アクセス・バスキュラー・インコーポレイテッド | 放出制御用高強度多孔質材料 |
| AU2021230387A1 (en) | 2020-03-06 | 2022-11-03 | Access Vascular, Inc. | Packaging for hydrated articles and related methods |
| AU2021300951A1 (en) | 2020-06-30 | 2023-02-09 | Access Vascular, Inc. | Articles comprising markings and related methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5470705A (en) | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP3628614B2 (ja) | 1999-03-15 | 2005-03-16 | アプレラ コーポレイション | 多重核酸検出のためのプローブ／移動度モディファイア複合体 |
| AU2001265121A1 (en) | 2000-05-30 | 2001-12-11 | Applera Corporation | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| CA2485691A1 (en) | 2002-05-20 | 2003-12-04 | Abgenix, Inc. | Treatment of renal carcinoma using antibodies against the egfr |
| CN104774931B (zh) * | 2004-03-31 | 2017-11-10 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
| US7932026B2 (en) | 2004-06-04 | 2011-04-26 | Genentech, Inc. | EGFR mutations |
| BRPI0607235A2 (pt) | 2005-02-24 | 2009-08-25 | Amgen Inc | mutações do receptor do fator de crescimento epidérmico |
| CN102007220A (zh) * | 2005-04-01 | 2011-04-06 | 安姆根有限公司 | 表皮生长因子受体基因拷贝数 |
| US20090269344A1 (en) * | 2005-04-14 | 2009-10-29 | Salvatore Siena | Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues |
| ES2398709T5 (es) * | 2005-06-28 | 2017-04-18 | Genentech, Inc. | Mutaciones en EGFR y KRAS para predecir la respuesta de un paciente al tratamiento con inhibidores de EGFR |
| WO2007109571A2 (en) * | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| KR101053738B1 (ko) * | 2006-08-10 | 2011-08-02 | 가부시키가이샤 우부카타 세이사쿠쇼 | 열응동 개폐기 |
| AR065686A1 (es) * | 2007-03-13 | 2009-06-24 | Amgen Inc | Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr |
| PE20081880A1 (es) * | 2007-03-13 | 2008-12-31 | Amgen Inc | Mutaciones de k-ras y terapia con anticuerpos anti-egfr |
-
2008
- 2008-03-11 AR ARP080100994A patent/AR065686A1/es unknown
- 2008-03-11 MX MX2009009779A patent/MX2009009779A/es active IP Right Grant
- 2008-03-11 PE PE2008000450A patent/PE20090690A1/es not_active Application Discontinuation
- 2008-03-11 RS RS20130374A patent/RS52932B/sr unknown
- 2008-03-11 PT PT111843561T patent/PT2412828E/pt unknown
- 2008-03-11 TW TW097108518A patent/TW200904828A/zh unknown
- 2008-03-11 SI SI200831031T patent/SI2412828T1/sl unknown
- 2008-03-11 US US12/046,312 patent/US20090075267A1/en not_active Abandoned
- 2008-03-11 EP EP11184356.1A patent/EP2412828B1/en not_active Revoked
- 2008-03-11 PL PL11184356T patent/PL2412828T3/pl unknown
- 2008-03-11 AU AU2008226808A patent/AU2008226808B2/en not_active Ceased
- 2008-03-11 JP JP2009553625A patent/JP2010521154A/ja not_active Withdrawn
- 2008-03-11 DK DK11184356.1T patent/DK2412828T3/da active
- 2008-03-11 CA CA002680330A patent/CA2680330A1/en not_active Abandoned
- 2008-03-11 CL CL200800716A patent/CL2008000716A1/es unknown
- 2008-03-11 ES ES11184356T patent/ES2426814T3/es active Active
- 2008-03-11 EP EP08742064A patent/EP2118322A2/en not_active Withdrawn
- 2008-03-11 WO PCT/US2008/003327 patent/WO2008112274A2/en not_active Ceased
-
2010
- 2010-12-22 US US12/976,895 patent/US20110212456A1/en not_active Abandoned
-
2013
- 2013-07-19 CY CY20131100612T patent/CY1114159T1/el unknown
- 2013-08-12 HR HRP20130764AT patent/HRP20130764T1/hr unknown
- 2013-09-12 JP JP2013189299A patent/JP5905422B2/ja active Active
-
2015
- 2015-02-23 JP JP2015032611A patent/JP2015119726A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP5905422B2 (ja) | 2016-04-20 |
| RS52932B (sr) | 2014-02-28 |
| ES2426814T3 (es) | 2013-10-25 |
| EP2412828B1 (en) | 2013-06-05 |
| CY1114159T1 (el) | 2016-08-31 |
| AR065686A1 (es) | 2009-06-24 |
| AU2008226808A1 (en) | 2008-09-18 |
| PE20090690A1 (es) | 2009-06-22 |
| US20090075267A1 (en) | 2009-03-19 |
| AU2008226808B2 (en) | 2013-04-18 |
| PT2412828E (pt) | 2013-08-02 |
| CA2680330A1 (en) | 2008-09-18 |
| JP2010521154A (ja) | 2010-06-24 |
| HRP20130764T1 (hr) | 2013-10-25 |
| US20110212456A1 (en) | 2011-09-01 |
| DK2412828T3 (da) | 2013-09-02 |
| EP2412828A1 (en) | 2012-02-01 |
| WO2008112274A3 (en) | 2008-12-18 |
| TW200904828A (en) | 2009-02-01 |
| WO2008112274A2 (en) | 2008-09-18 |
| JP2013253105A (ja) | 2013-12-19 |
| SI2412828T1 (sl) | 2013-10-30 |
| CL2008000716A1 (es) | 2008-09-22 |
| EP2118322A2 (en) | 2009-11-18 |
| HK1167005A1 (en) | 2012-11-16 |
| JP2015119726A (ja) | 2015-07-02 |
| PL2412828T3 (pl) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009779A (es) | Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr. | |
| MX2009009787A (es) | Mutaciones de k-ras y terapia con anticuerpos anti-egfr. | |
| JOP20190017B1 (ar) | أجسام مضادة ترتبط مع مستقبل cgrp بشري | |
| PH12018550164A1 (en) | Bcma binding molecules and methods of use thereof | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| EA200800094A1 (ru) | Антитела cd19 и их использование | |
| MX2009006277A (es) | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. | |
| WO2007103770A3 (en) | Compositions and methods for analyzing renal cancer | |
| UA95068C2 (uk) | Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| WO2008097466A3 (en) | Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors | |
| MX2010008096A (es) | Anticuerpos de ferroportina y metodos de uso. | |
| MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
| MX2009013410A (es) | Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta. | |
| UA98983C2 (uk) | Антитіло проти гепсидину та його застосування | |
| MX2011011075A (es) | Anticuerpos especificos para cadherina-17. | |
| MX2011009220A (es) | Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1. | |
| NZ602840A (en) | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor | |
| WO2008151819A3 (en) | Treatment of tumors using specific anti-l1 antibody | |
| WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
| EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
| SG155931A1 (en) | Wnt proteins and detection and treatment of cancer | |
| WO2005033133A3 (en) | Polynucleotides encoding erbb-2 polypeptides and kits and methods using same | |
| TW200517122A (en) | Antibodies specific for cancer associated antigen SM5-1 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |